1000698-98-5

Usage

Physical state

Colorless liquid

Odor

Characteristic odor

Uses

a. Production of pharmaceuticals
b. Production of agrochemicals
c. Synthesis of various organic compounds
d. Production of specialty chemicals
e. Reagent in organic reactions
f. Development of new materials
g. Medicinal chemistry research

Chemical properties

a. Strong nucleophile
b. Isocyanate precursor

Safety precautions

Toxic and may cause irritation to skin, eyes, and respiratory system

Handling guidelines

Follow proper safety precautions and guidelines

Upstream product

• 1448309-95-2 N-(4,4-difluorocyclohexyl)formamide 
• 96042-30-7 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 
• 224309-64-2 tert-butyl N-(4-hydroxycyclohexyl)carbamate 
• 675112-70-6 4,4-difluorocyclohexylamine hydrochloride 
• 675112-67-1 tert-butyl (4,4-difluorocyclohexyl)carbamate 
• 179321-49-4 N-(tert-butoxycarbonyl)-4-aminocyclohexanone 
• 458566-84-2 4,4-difluorocyclohexan-1-amine 
• 67-66-3 chloroform 

Downstream Products

• 1448348-03-5 (S)-N-(1-(2-chlorophenyl)-2-((4,4-difluorocyclohexyl)amino)-2-oxoethyl)-N-(3-fluoro-phenyl)-5-oxopyrrolidine-2-carboxamide 
• 1448309-79-2 (2S,5S)-N-((R)-1-(2-chlorophenyl)-2-(4,4-difluorocyclohexylamino)-2-oxoethyl)-N-(3-fluorophenyl)-5-methyl-1-(pyrimidin-2-yl)pyrrolidine-2-carboxamide 
• 1448309-80-5 (2S,5S)-N-((S)-1-(2-chlorophenyl)-2-(4,4-difluorocyclohexylamino)-2-oxo ethyl)-N-(3-fluorophenyl)-5-methyl-1-(pyrimidin-2-yl)pyrrolidine-2-carboxamide 
• 1297603-77-0 C₃₂H₄₀ClF₂N₃O₄ 

Relevant academic research and scientific papers

Discovery and structure-activity-relationship study of novel conformationally restricted indane analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors

The discovery and optimization of various of indane amides as mutant IDH1 inhibitors via structure-based rational design were reported. The optimal compounds demonstrated both potent inhibition in IDH1R132H enzymatic activity and 2HG production in IDH1 mutant HT1080 cell line, favorable PK properties and great selectivity against IDH1wt and IDH2R140Q.

Iridinesulfonamide compound and use method thereof

An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically-acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation-induced cancers.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF

Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1 comprising administering to a subject in need thereof a compound described here.